Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: shero who wrote (2484)	8/29/1998 2:00:00 AM
From: Terry D.	Read Replies (1) \| Respond to of 3702

Post from yahoo golfdad mangas2 golfdad97 (55/M/Houston TX) Aug 28 1998 3:13PM EDT Your points are well taken, but perhaps a couple of additional caveats may be entertained. First, clinical responses in glioma can be obtained by standard megavolt radiation and attempts to confine radiation to the malignant field have advanced greatly by "coning" techniques. Newer methodologies include administration of a variety of targeting, radiolabeled (or toxin-labeled) antibodies by both intravenous and interstitial routes. Recurrent disease usually appears just outside the radiation field. However, in contrast to what you view as a lack of earthshaking enthusiasm...it may be of some value to consider that the interim results given in the news release were PHASE I studies, in patients who have recurrent disease (with possible further CNS involvement) who are probably refractory to further therapies. Hence, TNT-mediated radiation was not "competing" with other front-line therapy in initial treatment, but was limited to an evaluation of imaging and total body dosing, as well as localization of the 131-I to the brain tissue. Clearly, even in these Phase I patients, CLINICAL BENEFIT WAS OBSERVED, while in other clinical Phase I trials of other tumor types (say recurrent visceral disease of melanoma or colon carcinoma) one rarely observes any clinical benefit. So, in that respect, I believe the interim news is better than expected. These are probably the results to be presented in greater detail (with imaging slides, etc) to the Neuro-Oncology Society in November, 1998. I see today's news as extremely encouraging for this modality. In fact, I see this news as actually being able to speed up the initiation of Phase II regarding this use of TNT, because clinical benefit may be readily apparent.Regarding today's news...I agree with Tawny...in that this is only the beginning.In postscript, I add, welcome to the board, Megster. Just a copy and paste kind of guy. Terry